352
Participants
Start Date
October 1, 2020
Primary Completion Date
February 1, 2021
Study Completion Date
March 30, 2021
olanzapine plus fosaprepitant-based triple regimen
olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
placebo plus fosaprepitant-based triple regimen
placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
Beijing Cancer Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Hunan Cancer Hospital, Changsha
Sichuan Cancer Hospital& Institute, Chengdoucun
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Sun Yat-sen University Cancer Center, Guangdong
Harbin Medical University Cancer Hospital, Haerbin
Anhui Provincial Cancer Hospital, Hefei
Yunnan Cancer Hospital, Kunming
Jiangxi Cancer Hospital, Nanchang
Guangxi Medical University Affiliated Tumor Hospital, Nanning
Ningbo Medical Center Lihuili Hospital, Ningbo
Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai
Liaoning Cancer Hospital & Institute, Shenyang
Fourth Hospital of Hebei Medical University, Shijiazhuang
The First Affiliated Hospital of Soochow University, Suzhou
Tianjin Medical University General Hospital, Tianjin
Henan Cancer Hospital, Zhengzhou
Collaborators (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INDUSTRY
Sun Yat-sen University
OTHER